To evaluate the actual effectiveness of our two-step analysis platform (Fig. 3) in a routine diagnostic setting, we reviewed effort and outcome of KRAS codon 12/13 mutation testing in 120 independent colorectal cancer samples that were examined consecutively in our laboratory according to this concept (Table 3). This evidence concerns the gene KRAS and colorectal cancer.